Clinical Trial Detail

NCT ID NCT03625323
Title Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Immutep S.A.
Indications

laryngeal squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma

oral squamous cell carcinoma

lung non-small cell carcinoma

hypopharynx cancer

Therapies

Eftilagimod alpha + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST